Purewater Capital LLC Acquires New Position in Boston Scientific Corporation $BSX

Purewater Capital LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 36,753 shares of the medical equipment provider’s stock, valued at approximately $1,604,000. Boston Scientific comprises about 1.3% of Purewater Capital LLC’s investment portfolio, making the stock its 17th largest position.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kingswood Wealth Advisors LLC grew its position in Boston Scientific by 14.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 12,315 shares of the medical equipment provider’s stock worth $538,000 after purchasing an additional 1,553 shares during the period. Broadway Wealth Solutions Inc. lifted its holdings in shares of Boston Scientific by 9.9% in the 3rd quarter. Broadway Wealth Solutions Inc. now owns 7,562 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 681 shares during the period. Bernardo Wealth Planning LLC acquired a new position in shares of Boston Scientific in the 3rd quarter valued at about $426,000. Signaturefd LLC lifted its holdings in shares of Boston Scientific by 28.7% in the 3rd quarter. Signaturefd LLC now owns 37,176 shares of the medical equipment provider’s stock valued at $1,623,000 after buying an additional 8,286 shares during the period. Finally, McGuire Investment Group LLC boosted its stake in shares of Boston Scientific by 1.0% in the third quarter. McGuire Investment Group LLC now owns 73,023 shares of the medical equipment provider’s stock worth $3,187,000 after buying an additional 731 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several analyst reports. Needham & Company LLC dropped their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Rothschild & Co Redburn decreased their price target on Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Evercore decreased their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a report on Wednesday, October 7th. The Goldman Sachs Group lowered their price objective on Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Finally, Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $68.23.

Boston Scientific Trading Down 0.0%

BSX stock opened at $45.67 on Monday. The company’s 50-day simple moving average is $45.46 and its 200-day simple moving average is $49.06. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The firm has a market cap of $66.19 billion, a P/E ratio of 18.49, a PEG ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $0.75 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, Director David Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.